A 60-year-old man attends a routine diabetes review. He was diagnosed with type 2 diabetes 18 months ago and is taking metformin 1 g twice daily. His latest HbA1c is 51 mmol/mol (6.8%). Two years ago he had an acute coronary syndrome and underwent PCI. Current meds include an ACE inhibitor, a high-intensity statin, and antiplatelet therapy. BP is 128/76 mmHg and he feels well.
What is the best next step in glucose-lowering therapy?
A. Add a thiazolidinedione (pioglitazone)
B. Add a short-acting insulin secretagogue (meglitinide)
C. Add an alpha-glucosidase inhibitor (acarbose)
D. Add a SGLT-2 inhibitor
E. Continue metformin alone and recheck HbA1c in 12 months
Answer: D. Add a SGLT-2 inhibitor
Detailed discussion for MRCP
Why the SGLT2 inhibitor is the best answer here
In type 2 diabetes, modern guidance is risk-based, not purely “glucose-number-based.” If a person has established atherosclerotic cardiovascular disease (ASCVD) (e.g., prior MI/ACS/PCI), then an SGLT2 inhibitor with proven cardiovascular benefit should be offered in addition to metformin (once metformin tolerability is established), even if HbA1c is already close to target. The rationale is that SGLT2 inhibitors provide cardio-renal protection that is partly independent of glucose lowering (reducing heart failure events and slowing CKD progression; also beneficial CV outcomes in many groups). NICE NG28 recommendations explicitly incorporate offering/considering SGLT2 inhibitors based on heart failure / established ASCVD / high CV risk, and visual summaries highlight adding SGLT2i if the person “develops CVD or high risk of CVD.” (NICE)
Core MRCP principle tested
If T2DM + established ASCVD or heart failure (or significant CKD/proteinuria depending on licensing) → prioritize SGLT2 inhibitor (or GLP-1 RA in some algorithms) for outcome benefit, not just HbA1c.
Mechanism (know this cold)
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) block SGLT2 in the proximal renal tubule, reducing glucose (and sodium) reabsorption → glycosuria + natriuresis.
- Metabolic effects: modest HbA1c reduction, weight loss, small BP reduction.
- Hemodynamic/renal effects: reduced intraglomerular pressure, improved tubuloglomerular feedback; natriuresis and plasma volume effects help HF outcomes.
What counts as “established ASCVD”
Typical examples: previous MI/ACS, stable angina, coronary revascularisation, ischaemic stroke/TIA, peripheral arterial disease. (myastrazeneca.co.uk)
Why not the other options
- Pioglitazone (TZD): can improve insulin sensitivity but causes weight gain, fluid retention, can precipitate/worsen HF; not the preferred “ASCVD-protection” add-on.
- Meglitinide / sulfonylurea-like secretagogues: lower glucose but hypoglycaemia + weight gain, no cardio-renal outcome advantage.
- Acarbose: modest benefit, GI side effects, not outcome-driven choice for ASCVD.
- “Do nothing because HbA1c ok”: misses the point—CVD presence changes the priority; you treat risk and outcomes, not just HbA1c. (NICE)
High-yield safety counselling (commonly examined)
Know the “don’t-miss” adverse effects and sick-day rules:
- Genital mycotic infections (thrush, balanitis), UTIs (less strongly), perineal discomfort.
- Volume depletion / postural hypotension (esp. elderly, diuretics).
- Euglycaemic DKA (rare but critical): can occur with relatively normal glucose.
- Triggers: fasting, dehydration, acute illness, surgery, low-carb dieting, excess alcohol, insulin omission.
- Counsel: stop during acute illness (“sick day rules”), seek help for nausea/vomiting/abdominal pain/breathlessness; check ketones if unwell.
- Fournier’s gangrene (very rare): severe genital/perineal pain/swelling/fever → urgent care.
- Amputation/fracture signals were mainly a canagliflozin signal historically; in exams, emphasise foot care, caution in severe PAD/active ulcers (local policies vary).
Renal function considerations
- Glycaemic efficacy falls at lower eGFR, but cardiorenal benefits may persist depending on agent/indication.
- Practical MRCP approach: before starting, check eGFR, volume status, and concurrent diuretics; follow local/BNF thresholds for the specific drug/indication.
Where GLP-1 receptor agonists fit (likely viva/OSCE add-on)
GLP-1 RAs also have CV benefit (especially atherosclerotic outcomes) and promote weight loss. In many pathways they are chosen when:
- weight loss is a major goal,
- SGLT2i is contraindicated/not tolerated,
- additional glycaemic/weight control needed.
But in this stem, the single best next step (ASCVD + on metformin) remains SGLT2 inhibitor per NICE risk-based approach. (NICE)
Cheat sheet
- T2DM first line: lifestyle + metformin (titrate; MR if GI intolerance).
- Add 2nd agent by HbA1c threshold unless comorbidity drives earlier choice.
- If chronic HF or established ASCVD: offer SGLT2 inhibitor with proven CV benefit (+ metformin if tolerated). (NICE)
- If high CV risk (e.g., QRISK ≥10% in NICE framework): consider SGLT2 inhibitor (+ metformin). (NICE)
- SGLT2i benefits: ↓HF hospitalisation, slows CKD progression; modest ↓HbA1c, ↓weight, ↓BP.
- Key cautions: genital thrush, dehydration/postural drop, euglycaemic DKA (sick-day stop), Fournier’s (rare).
- Avoid/think twice: recurrent DKA risk, severe dehydration, very frail with falls risk, active foot ulcers/severe PAD (context-specific).
- Always combine with: BP control (ACEi/ARB if indicated), statin, antiplatelet if secondary prevention, smoking cessation.
Flash cards
- Q: In T2DM, what comorbidity makes you add an SGLT2 inhibitor even if HbA1c is near target?
A: Established ASCVD or chronic heart failure (and often CKD indications).
Explanation: Outcome benefit is prioritized over glycaemic threshold. - Q: Give 4 examples of established ASCVD.
A: Prior MI/ACS, PCI/CABG, ischaemic stroke/TIA, peripheral arterial disease.
Explanation: These are classic “established ASCVD” categories. - Q: What is the primary site of action of SGLT2 inhibitors?
A: SGLT2 transporter in the proximal renal tubule.
Explanation: Causes glycosuria and natriuresis. - Q: Two metabolic “extras” of SGLT2 inhibitors beyond HbA1c reduction?
A: Weight loss and small BP reduction.
Explanation: Calorie loss via glycosuria + natriuresis. - Q: The most exam-critical rare adverse effect of SGLT2 inhibitors?
A: Euglycaemic diabetic ketoacidosis (DKA).
Explanation: Can occur with normal-ish glucose; recognise triggers. - Q: List 4 triggers for SGLT2i-associated euglycaemic DKA.
A: Fasting, dehydration/acute illness, surgery, very low-carb diet/alcohol excess/insulin omission.
Explanation: All shift metabolism toward ketogenesis. - Q: What “sick day rule” should you teach with SGLT2 inhibitors?
A: Hold the drug during acute illness (vomiting, dehydration, poor intake) and peri-operatively; seek help if DKA symptoms.
Explanation: Reduces DKA risk. - Q: Most common day-to-day adverse effect patients notice?
A: Genital mycotic infection (thrush/balanitis).
Explanation: More glucose in urine supports fungal growth. - Q: Why can SGLT2 inhibitors worsen dizziness/falls in older adults?
A: Osmotic diuresis → volume depletion and postural hypotension.
Explanation: Especially with diuretics. - Q: Why is pioglitazone often avoided in HF?
A: Fluid retention can precipitate/worsen heart failure.
Explanation: TZD side effect is oedema/weight gain. - Q: Why are sulfonylureas less attractive in ASCVD-focused care?
A: Hypoglycaemia and weight gain, without proven CV outcome benefit.
Explanation: They lower glucose but not CV events. - Q: Which class is best for weight loss: SGLT2i, DPP-4i, sulfonylurea?
A: SGLT2i (modest loss) vs DPP-4i (weight neutral) vs sulfonylurea (gain).
Explanation: Classic exam comparison. - Q: Which drug class is weight neutral and low hypoglycaemia risk but minimal CV benefit?
A: DPP-4 inhibitors.
Explanation: Safe but not outcome-driven like SGLT2i. - Q: What lab value should be checked before starting an SGLT2 inhibitor?
A: Renal function (eGFR) and baseline electrolytes; assess volume status.
Explanation: Dosing/eligibility and safety. - Q: What is “proven cardiovascular benefit” referring to?
A: Trial evidence of reducing CV outcomes (often HF hospitalisation and/or MACE) for specific SGLT2 agents.
Explanation: Not all agents have identical evidence. - Q: In NICE risk-based language, what is “offer” vs “consider”?
A: “Offer” = strong recommendation; “consider” = depends on patient factors/preferences.
Explanation: Helps pick best answer in SBA stems. - Q: When metformin is not tolerated and the patient has established ASCVD, what can be first-line?
A: SGLT2 inhibitor monotherapy (agent/indication dependent).
Explanation: NICE includes SGLT2i when metformin contraindicated/not tolerated. (NICE) - Q: Name a very rare but life-threatening soft tissue infection linked to SGLT2 inhibitors.
A: Fournier’s gangrene.
Explanation: Perineal pain/swelling/fever → emergency. - Q: In an MRCP stem: HbA1c 52 mmol/mol, on metformin, prior MI—what’s the “exam move”?
A: Add an SGLT2 inhibitor (cardioprotective strategy).
Explanation: CVD overrides glycaemic threshold logic. - Q: If the main issue is obesity with need for marked weight loss and SGLT2i can’t be used, what class is a strong alternative?
A: GLP-1 receptor agonists.
Explanation: Weight loss + CV benefit in many pathways.
MCQs to test yourself
- A man with T2DM on metformin has HbA1c 50 mmol/mol and a previous MI. Best next add-on?
A. Acarbose
B. Add a SGLT-2 inhibitor
C. Nateglinide
D. Pioglitazone
E. Stop metformin and start diet alone
Answer: B. Explanation: Established ASCVD → SGLT2i for outcome benefit. - SGLT2 inhibitors lower glucose mainly by:
A. Increasing pancreatic insulin secretion
B. Blocking intestinal glucose absorption
C. Reducing hepatic gluconeogenesis
D. Increasing peripheral insulin sensitivity
E. Inhibiting proximal tubular glucose reabsorption
Answer: E. Explanation: SGLT2 blockade in proximal tubule → glycosuria. - Which of the following is false about SGLT2 inhibitors?
A. They can cause genital fungal infections
B. They may lead to volume depletion
C. They commonly cause severe hypoglycaemia when used alone
D. They can precipitate euglycaemic DKA
E. They may reduce heart failure hospitalisations
Answer: C. Explanation: Hypoglycaemia is uncommon with SGLT2i monotherapy. - A patient with T2DM and chronic heart failure is starting first-line therapy. Metformin is tolerated. Best evidence-based add-on class for outcome benefit?
A. Add a SGLT-2 inhibitor
B. DPP-4 inhibitor
C. Acarbose
D. Meglitinide
E. Colesevelam
Answer: A. Explanation: HF is a key driver for SGLT2i. - Which clinical situation most increases risk of euglycaemic DKA on an SGLT2 inhibitor?
A. High-carb diet
B. Acute gastroenteritis with poor intake
C. Mild seasonal rhinitis
D. Taking a multivitamin
E. Well-hydrated endurance training with adequate carbs
Answer: B. Explanation: Fasting/dehydration/illness → ketogenesis risk. - Which is the best counselling point when initiating SGLT2 inhibitors?
A. “Take extra salt to avoid hyponatraemia.”
B. “Expect frequent severe hypoglycaemia.”
C. “Stop it if you get a sore throat.”
D. “Maintain hydration and pause the drug during acute vomiting/poor intake.”
E. “Avoid all carbohydrates permanently.”
Answer: D. Explanation: Sick-day rules + hydration reduce DKA/volume depletion. - Which of the following is false regarding sulfonylureas?
A. They can cause hypoglycaemia
B. They may cause weight gain
C. They have proven reduction in heart failure hospitalisation
D. They stimulate insulin secretion
E. They can reduce HbA1c effectively
Answer: C. Explanation: No proven HF outcome benefit like SGLT2i. - Established ASCVD includes all EXCEPT:
A. Peripheral arterial disease
B. Previous MI
C. Ischaemic stroke
D. Stable angina
E. Asthma
Answer: E. Explanation: Asthma is not ASCVD. - A 64-year-old with T2DM on metformin has HbA1c 57 mmol/mol, no CVD, but QRISK2 12%. Most appropriate next step (NICE-style logic)?
A. Add a SGLT-2 inhibitor
B. Add insulin immediately
C. Add acarbose
D. Add pramlintide
E. Stop metformin
Answer: A. Explanation: High CV risk → consider SGLT2i with proven CV benefit. - Which effect is most typical of SGLT2 inhibitors?
A. Weight gain
B. Bradycardia
C. Modest weight loss
D. Severe constipation
E. Hyperkalaemia as the dominant effect
Answer: C. Explanation: Glycosuria → calorie loss; plus natriuresis. - Which of the following is false about DPP-4 inhibitors?
A. Generally weight neutral
B. Low hypoglycaemia risk when used alone
C. Provide robust heart failure outcome benefit comparable to SGLT2i
D. Used as an option for add-on glucose lowering
E. Act by increasing endogenous incretin action
Answer: C. Explanation: They do not match SGLT2i HF benefits. - A patient on SGLT2 inhibitor develops severe perineal pain, swelling, and fever. Best action?
A. Reassure and continue
B. Topical steroid and review in 2 weeks
C. Start oral iron
D. Suspect Fournier’s gangrene and arrange urgent admission
E. Switch to acarbose only
Answer: D. Explanation: Rare emergency. - Which is the most plausible cause of postural dizziness soon after starting an SGLT2 inhibitor?
A. Osmotic diuresis causing volume depletion
B. Bone marrow suppression
C. Central vestibular toxicity
D. Profound hypoglycaemia in all patients
E. Thyrotoxicosis
Answer: A. Explanation: Natriuresis/diuresis → lower volume/BP. - Which of the following is false about adding SGLT2 inhibitors in T2DM with ASCVD?
A. Can be recommended even if HbA1c is near target
B. Benefits can extend beyond glycaemic control
C. They always require concurrent sulfonylurea
D. They may reduce HF hospitalisation risk
E. They should be considered within a risk-based approach
Answer: C. Explanation: No requirement for sulfonylurea. - In a T2DM patient without ASCVD/HF/CKD, on metformin, when is escalation commonly considered in older NICE-style HbA1c logic?
A. When HbA1c rises above an agreed threshold (often around 58 mmol/mol depending on context)
B. Immediately at diagnosis for everyone
C. Only when HbA1c exceeds 100 mmol/mol
D. Only if fasting glucose is low
E. Never escalate
Answer: A. Explanation: Glycaemic threshold approach applies when no outcome-driven comorbidity. - Which choice is most associated with weight gain?
A. DPP-4 inhibitor
B. SGLT2 inhibitor
C. GLP-1 receptor agonist
D. Sulfonylurea
E. Acarbose
Answer: D. Explanation: Sulfonylureas commonly cause weight gain. - Which of the following is false about GLP-1 receptor agonists?
A. Promote weight loss
B. Can reduce HbA1c
C. Often cause GI side effects early
D. Always cause severe hypoglycaemia as monotherapy
E. Can be useful when weight loss is a priority
Answer: D. Explanation: Hypoglycaemia is uncommon unless combined with insulin/SU. - A patient on metformin has HbA1c 52 mmol/mol and is newly diagnosed with stable angina. Best next step for diabetes meds?
A. Add acarbose
B. Add a meglitinide
C. Add a SGLT-2 inhibitor
D. Stop metformin
E. Add bromocriptine
Answer: C. Explanation: Developing ASCVD → add SGLT2i for CV benefit. - Which is the best single screening question before starting SGLT2 inhibitors to reduce serious harm?
A. “Do you like spicy food?”
B. “Do you have recurrent genital infections or prior DKA / very low-carb dieting?”
C. “Do you prefer morning showers?”
D. “Are you left-handed?”
E. “Do you drink coffee?”
Answer: B. Explanation: Identifies higher-risk features; counsel sick-day rules. - Which of the following is false regarding SGLT2 inhibitors?
A. Can increase risk of genital candidiasis
B. Can be associated with euglycaemic DKA
C. Can cause osmotic diuresis
D. Typically cause weight gain of >10 kg
E. May have cardiorenal protective effects
Answer: D. Explanation: They usually cause modest weight loss, not large weight gain. - In a patient with HF and T2DM, which class has the strongest consistent trial signal for reducing HF hospitalisations?
A. Sulfonylureas
B. SGLT2 inhibitors
C. Alpha-glucosidase inhibitors
D. Meglitinides
E. Bile acid sequestrants
Answer: B. Explanation: Core SGLT2i outcome benefit. - Which option is MOST appropriate if metformin is contraindicated and the patient has established ASCVD?
A. DPP-4 inhibitor as the only possible option
B. Immediate basal-bolus insulin for everyone
C. Offer an SGLT2 inhibitor with proven cardiovascular benefit (as suitable monotherapy)
D. Acarbose first line universally
E. No pharmacotherapy allowed
Answer: C. Explanation: NICE supports SGLT2i use when metformin can’t be used in ASCVD/HF contexts. (NICE)
Summary for quick exam revision
In type 2 diabetes, treatment escalation is no longer driven only by HbA1c thresholds; comorbid cardiovascular and renal disease can mandate earlier therapy for outcome benefit. If a patient on metformin has established atherosclerotic cardiovascular disease (e.g., prior MI/ACS/PCI, stroke/TIA, PAD) or chronic heart failure, an SGLT2 inhibitor with proven cardiovascular benefit should be added even when HbA1c is near target, because benefits extend beyond glucose lowering. SGLT2 inhibitors act in the proximal tubule to cause glycosuria and natriuresis, producing modest HbA1c reduction, weight loss, and BP lowering, while reducing heart failure events and slowing CKD progression in many patients. Key adverse effects are genital fungal infections, volume depletion/postural hypotension, rare euglycaemic DKA (triggered by fasting, dehydration, illness, surgery, low-carb diets, alcohol, insulin omission), and very rare Fournier’s gangrene; teach hydration and sick-day stopping rules. Sulfonylureas and meglitinides lower glucose but cause hypoglycaemia and weight gain without cardio-renal outcome advantage, while DPP-4 inhibitors are weight neutral with low hypoglycaemia risk but lack the same outcome benefits. Always manage the whole risk profile alongside glucose: statin, BP control (ACEi/ARB when indicated), antiplatelet therapy for secondary prevention, and lifestyle measures.